These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32110103)

  • 1. Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study.
    Yang X; Bai Y; Shi M; Zhang W; Niu J; Wu C; Zhang L; Xu Z; Liu X; Chen Y; Sun K
    Cancer Manag Res; 2020; 12():1293-1301. PubMed ID: 32110103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.
    Sato E; Iriyama N; Tokuhira M; Takaku T; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Kimura Y; Fujioka I; Asou N; Komatsu N; Kizaki M; Hatta Y; Kawaguchi T
    Cancer Med; 2020 Dec; 9(23):8931-8939. PubMed ID: 33037866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy.
    Xia L; Qian W; Yang M; Li Q; Liu F; Xie Y
    Onco Targets Ther; 2015; 8():2485-92. PubMed ID: 26392775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
    Uz B; Buyukasik Y; Atay H; Kelkitli E; Turgut M; Bektas O; Eliacik E; Isik A; Aksu S; Goker H; Sayinalp N; Ozcebe OI; Haznedaroglu IC
    Hematology; 2013 Sep; 18(5):247-52. PubMed ID: 23540886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?
    Zhang XS; Gale RP; Huang XJ; Jiang Q
    Leukemia; 2022 Feb; 36(2):482-491. PubMed ID: 34413457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Three Prognostic Scoring Systems in Predicting the Response and Outcome in Pediatric Chronic Myeloid Leukemia Chronic Phase on Frontline Imatinib.
    Ganta RR; Nasaka S; Linga VG; Gundeti S; Maddali LS; Digumarti RR
    Indian J Med Paediatr Oncol; 2017; 38(3):282-286. PubMed ID: 29200674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of Sokal and Eutos Scores for Predicting Cytogenetic and Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients on Imatinib.
    Ganguly S; Lakshmaiah KC; Jacob LA; Babu S; Dasappa L; Govind Babu KS
    Indian J Hematol Blood Transfus; 2017 Mar; 33(1):82-86. PubMed ID: 28194061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia.
    Huang J; Wang L; Chen L; Qun H; Yajing X; Fangping C; Xielan Z
    Turk J Haematol; 2017 Mar; 34(1):10-15. PubMed ID: 27751981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients.
    Yamamoto E; Fujisawa S; Hagihara M; Tanaka M; Fujimaki K; Kishimoto K; Hashimoto C; Itabashi M; Ishibashi D; Nakajima Y; Tachibana T; Kawasaki R; Kuwabara H; Koharazawa H; Yamazaki E; Tomita N; Sakai R; Fujita H; Kanamori H; Ishigatsubo Y
    Cancer Sci; 2014 Jan; 105(1):105-9. PubMed ID: 24450386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical significance of Sokal, Hasford and EUTOS prognostic scoring systems in chronic myeloid leukemia].
    Feng G; Wang J; Jiang Y; Li Y; Ding M; Wang N; Wang X
    Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):743-6. PubMed ID: 25152126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of a nomogram to predict poor efficacy of imatinib in the treatment of newly diagnosed chronic phase chronic myeloid leukemia patients.
    Li Y; Zhang Y; Wang J; He A; Zhang W; Cao X; Chen Y; Liu J; Zhang P; Wang J; Zhao W; Yang Y; Meng X; Chen S; Zhang L; Wang T; Wang X; Ma X
    Front Oncol; 2024; 14():1418417. PubMed ID: 38978732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Values of Different Prognostical Score Systems in Evaluation of Clinical Efficacy for Patients with Newly Diagnosed Chronic Myeloid Leukemia].
    Wang PP; Zhang PP; Zhang J; Xi YM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):723-728. PubMed ID: 31204922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of three prognostic scoring systems on evaluating the prognosis for patients with chronic myeloid leukemia].
    Huang J; Zhao X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 41(8):809-14. PubMed ID: 27600007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
    Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
    Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib.
    Tao Z; Liu B; Zhao Y; Wang Y; Zhang R; Han M; Zhang L; Li C; Ru K; Mi Y; Wang J
    Leuk Res; 2014 Sep; 38(9):1030-5. PubMed ID: 24996976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A scoring system to predict molecular responses in patients with chronic myeloid leukemia in the chronic phase receiving initial imatinib therapy].
    Li ZY; Zhang MY; Zhang XS; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):106-111. PubMed ID: 36948863
    [No Abstract]   [Full Text] [Related]  

  • 17. Can the Use of Bone Marrow Parameters Improve the Efficacy of Risk Prediction Scores in Chronic Myeloid Leukemia in Imatinib Era?
    Kanakasetty GB; Thanky AH; Kuntegowdanahalli L; Dasappa L; Jacob L; Mallekavu SB; Lakkavalli R; Kadabur L; Antapura R
    Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):375-381. PubMed ID: 28502460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia.
    Pfirrmann M; Clark RE; Prejzner W; Lauseker M; Baccarani M; Saussele S; Guilhot F; Heibl S; Hehlmann R; Faber E; Turkina A; Ossenkoppele G; Höglund M; Zaritskey A; Griskevicius L; Olsson-Strömberg U; Everaus H; Koskenvesa P; Labar B; Sacha T; Zackova D; Cervantes F; Colita A; Zupan I; Bogdanovic A; Castagnetti F; Guilhot J; Hasford J; Hochhaus A; Hoffmann VS
    Leukemia; 2020 Aug; 34(8):2138-2149. PubMed ID: 32601376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Stratification of Chronic Myeloid Leukemia According to Different Prognostic Scores.
    Aijaz J; Junaid N; Asif Naveed M; Maab R
    Cureus; 2020 Mar; 12(3):e7342. PubMed ID: 32313783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal, and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib.
    Ko PS; Yu YB; Liu YC; Wu YT; Hung MH; Gau JP; Liu CJ; Hsiao LT; Chen PM; Chiou TJ; Liu CY; Liu JH
    Curr Med Res Opin; 2017 Oct; 33(10):1737-1744. PubMed ID: 28715941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.